Loading
Marimed Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 16 Dec 2025.
Marimed Inc.: what insiders have been doing
Marimed Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 117 filings, from 14 insiders.
Every open-market trade in the period is a purchase: 4 purchases worth €6,955, from 2 insiders, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 2 senior executives among the declarants. Biggest ticket of the year: €4,147, bought by Shaw Timothy and made public on 16 December 2025.
The latest purchase dates back some time: it was published 144 days ago, on 26 May 2026. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 117 filings, this issuer sits above that mark. Over the whole record (from 2022), the tally stands at 4 purchases and no sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 159.8 m USD and net income at -14.5 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
175
Thresholds
n/a
Buy Volume
€6,955
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJon R. Levine3 buys
Timothy Shaw1 buy
Since the insiders bought
- -45.8%Entry US$0.14 · Close at T+90 US$0.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,382 of 24,148 companies
33.8
score / 100
Value46
Quality21
FCF yld25%
Earn yld-61%
EV/EBITDA13.4x
ROE-24%
Gross mgn36%
Net mgn-9.1%
Debt/EBITDA10.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.06
Analyst consensus
1 analysts1.00/5
US$0.25Target US$0.25(+324%)US$0.25
Income statement
RevenueUS$159.8M
Gross profitUS$57.9M36% margin
EBITDAUS$8.2M5% margin
Net income-US$14.5M-9.1% margin
Valuation
P/Book0.5x
Beta1.40
Balance sheet & cash
Market capUS$23.8M
Total debtUS$85.4M
Free Cash FlowUS$6.1M
Debt / Equity181%
Profitability & ownership
ROE-24.2%
ROA-0.6%
% insiders14.6%
% institutions1.0%
Last declaration on 15 October 2026
Declarations175 total
42,657 shares0Common stockSEC:0001522767-26-000210:0
12,520 shares@ US$0.06Common stockSEC:0001522767-26-000210:1
38,282 shares0Common stockSEC:0001522767-26-000208:0
11,236 shares@ US$0.06Common stockSEC:0001522767-26-000208:1
30,625 shares0Common stockSEC:0001522767-26-000206:0
8,989 shares@ US$0.06Common stockSEC:0001522767-26-000206:1
32,812 shares0Common stockSEC:0001522767-26-000204:0
9,631 shares@ US$0.06Common stockSEC:0001522767-26-000204:1
3,459 shares@ CA$0.06960.0006% mcap10.3% of flowCommon SharesTSXSEDI:4786433
9,981 sharesCommon SharesTSXSEDI:4786430
9,981 sharesRestricted Share UnitsTSXSEDI:4786427
3,991 shares@ CA$0.06960.0007% mcap4.1% of flowCommon SharesTSXSEDI:4786415
11,517 sharesCommon SharesTSXSEDI:4786414
11,517 sharesRestricted Share UnitsTSXSEDI:4786413
9,981 shares0Common stockSEC:0001522767-26-000197:0
11,517 shares0Common stockSEC:0001522767-26-000195:0
3,459 shares@ US$0.06960.0008% mcap3.1% of flowCommon stockSEC:0001522767-26-000197:1
3,991 shares@ US$0.06960.0009% mcap0.4% of flowCommon stockSEC:0001522767-26-000195:1
2,095 shares@ CA$0.0770.0004% mcap1.7% of flowCommon SharesTSXSEDI:4782534
6,046 sharesCommon SharesTSXSEDI:4782533
6,046 sharesRestricted Share UnitsTSXSEDI:4782532
6,046 shares0Common stockSEC:0001522767-26-000191:0
2,095 shares@ US$0.0770.0005% mcap8.3% of flowCommon stockSEC:0001522767-26-000191:1
65,000 shares0Common stockSEC:0001522767-26-000170:0
22,523 shares@ US$0.08160.0058% mcap23.3% of flowCommon stockSEC:0001522767-26-000170:1
25 of 175 declarations
About Marimed Inc.
MariMed Inc. is a U.S.-based cannabis operator headquartered in Norwood, Massachusetts, with public-market disclosure and communications tied to the U.S. market and a trading presence referenced in Nasdaq coverage; its securities are also quoted on OTCQX. For investors, the company should be viewed primarily as a multi-state cannabis consumer and brand platform rather than a pure cultivation story. MariMed develops, owns, and manages state-licensed, seed-to-sale facilities for the cultivation, production, and dispensing of medical and adult-use cannabis across the United States. Its model spans retail, wholesale, and brand licensing, giving it multiple revenue channels and a way to expand brand reach beyond company-owned stores. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai))
Historically, the company has evolved from a broader management-oriented cannabis platform into a more focused branded consumer-products strategy. SEC filings show a gradual buildout of owned facilities, licenses, and distribution capabilities, reflecting a long-term effort to create a more scalable, vertically integrated business. MariMed’s principal executive offices are located at 10 Oceana Way in Norwood, Massachusetts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai))
Read moreShow less
MariMed’s core business lines include cultivation, processing, retail dispensary operations, wholesale distribution, and intellectual-property monetization through product licensing. The company’s branded portfolio includes Nature’s Heritage, Betty’s Eddies, Kalm Fusion, Bubby’s Baked, Vibations, and InHouse. These brands cover premium flower, concentrates, edibles, fruit chews, chewable tablets, drink mixes, and other precisely dosed cannabis products. The strategic emphasis is on premium consumer packaged goods with repeat purchasing potential, which is a key differentiator in a fragmented and highly regulated market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000014/mrmd-20241231.htm?utm_source=openai))
In competitive terms, MariMed is positioned as a focused niche operator in a sector dominated by larger multi-state peers. Rather than competing only on cultivation scale, it aims to win through brand strength, product quality, and wholesale penetration. Management has said the company’s “Expand the Brand” strategy is intended to grow share in core markets and extend distribution into higher-growth states. That approach can be attractive for investors seeking exposure to branded cannabis products, but it also leaves the company exposed to pricing pressure and regulatory complexity in the wider U.S. cannabis market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1522767/000152276725000167/marimedq22025ex991.htm?utm_source=openai))
Recent developments are important for the investment case. In 2025, MariMed reported revenue growth, its sixth consecutive year of positive Adjusted EBITDA, and expanded distribution across a large portion of dispensaries in its core markets. It also highlighted new agreements intended to broaden the reach of its brands into Maine, Pennsylvania, and New York. In March 2026, the company reported its 2025 full-year results and said it had exited Missouri after a strategic review, signaling a more disciplined capital allocation approach and a focus on higher-return markets. ([nasdaq.com](https://www.nasdaq.com/press-release/marimed-reports-fourth-quarter-and-full-year-2025-earnings-2026-03-11?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
